• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zoetis and Danone Announce Strategic Partnership to Pioneer Sustainable Innovation in Dairy Farming Using the Power of Genetics

    9/26/24 9:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email

    Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today's dairy farms through the power of genetics for healthier cows. Combining Danone's commitment to environmental stewardship with Zoetis' expertise in animal genetics, the partnership aims to innovate the dairy industry's approach to breeding for sustainability.

    The plan between the two companies is intended to enable Danone to leverage Zoetis' cutting-edge genetic technologies globally. The focus is on integrating sustainable practices into dairy genetics and selection, emphasizing animal well-being, reducing environmental impact, and promoting long-term resilience in dairy farming.

    "Collaborative partnerships allow us to harmonize genetic innovation with sustainable practices. Through our partnership with Danone, we intend to leverage our respective expertise to set new benchmarks for healthier herds that contribute to a sustainable future for the dairy industry," said Wafaa Mamilli, EVP, Chief Digital & Technology Officer, and Group President for China, Brazil, and Precision Animal Health at Zoetis.

    As part of its commitment to equip dairy producers with innovative solutions to help them meet their sustainability goals, Zoetis' genetic testing solutions and expertise provide the ability to predict an animal's susceptibility to costly diseases and potential to remain healthy and productive over its lifetime - aligning with Danone's ambition to support dairy production that prioritizes environmental resiliency.

    "We really look forward to embarking with Zoetis on this journey. Together, we are committed to utilizing genomic testing as an important tool for incorporating sustainability at its core. This partnership aligns with our vision of creating positive change throughout the dairy value chain," said Jean-Yves Krummenacher, Chief Procurement Officer at Danone.

    Impacts of Genetics on Dairy Sustainability

    Zoetis became a member of Danone's global Partner for Growth program in 2023 as the preferred provider for genetic testing on dairy farms, specifically leveraging the Dairy Wellness Profit Index® (DWP$®) from CLARIFIDE® Plus. Only available through CLARIFIDE Plus, DWP$ is a multi-trait animal ranking selection index that reveals the value of critical wellness traits, including cow and calf wellness, production, fertility, functional type, longevity, livability, calving ability and milk quality traits, plus polled test results. Through this unique and comprehensive selection index, Zoetis can estimate the potential lifetime profit that Holstein and Jersey cattle will contribute to a dairy operation. Incorporating DWP$ into breeding and culling decisions helps dairy farmers create future generations of healthy, resilient animals capable of higher lifetime profit when combined with best management practices.1

    Zoetis brings innovation to the application of genetic testing by connecting how genetic improvements can help farmers work toward improving environmental, resource, and operational sustainability outcomes. Recent studies analyzing animal performance, genomic data, and financial records clearly indicate the potential benefits for sustainability, methane reduction, farm profitability, and animal welfare.2 Thus helping dairy producers to improve sustainable production practices over time while enhancing animal health and farm performance .2,†

    The partnership aspires to positively impact the environment, increase cow longevity, improve farm resilience, and meet the increasing consumer demand for sustainably sourced dairy products. Visit ClarifidePlus.com to learn more about Zoetis' comprehensive portfolio of dairy genetic solutions.

    About Zoetis

    As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

    † This is based on generally accepted calculation (not actual measurement of methane emissions).

    1 Fessenden, B., et al. Validation of genomic predictions for a lifetime merit selection index for the US dairy industry.

    J Dairy Sci. 2020;103(11):10414-10428.

    2 Di Croce F. Championing a Healthier, More Sustainable Future Through Genetics, July 2022; Zoetis Inc.

    All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

    © 2024 Zoetis Services LLC. All rights reserved. CLR-00591

    ZTS-FA

    ZTS-COR

    ZTS-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240925718835/en/

    Get the next $ZTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    1/22/2026$135.00Overweight → Neutral
    Piper Sandler
    12/15/2025$135.00Buy → Neutral
    BofA Securities
    12/9/2025$136.00Equal Weight
    Barclays
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    More analyst ratings

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on May 7, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur

    4/2/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum

    Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 10:30 a.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, an

    3/12/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Participate in Upcoming Investor Conferences

    Zoetis Inc. (NYSE:ZTS) today announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will participate in fireside chats at the following investor conferences. Leerink Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 9:30 a.m. ET Interested parties can access live audio webcasts of the presentations by visiting https://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our

    3/5/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00

    1/22/26 8:26:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zoetis from Buy to Neutral and set a new price target of $135.00

    12/15/25 9:58:23 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Zoetis with a new price target

    Barclays initiated coverage of Zoetis with a rating of Equal Weight and set a new price target of $136.00

    12/9/25 8:55:22 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ZTS
    SEC Filings

    View All

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    SEC Form 4 filed by Sarbaugh Keith

    4 - Zoetis Inc. (0001555280) (Issuer)

    4/1/26 4:29:29 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fuller Julie

    4 - Zoetis Inc. (0001555280) (Issuer)

    3/31/26 4:47:16 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Peck Kristin C

    4 - Zoetis Inc. (0001555280) (Issuer)

    3/31/26 4:47:03 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Zoetis Inc.

    DEF 14A - Zoetis Inc. (0001555280) (Filer)

    4/8/26 9:01:42 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Zoetis Inc.

    DEFA14A - Zoetis Inc. (0001555280) (Filer)

    4/8/26 9:02:53 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zoetis Inc.

    SCHEDULE 13G/A - Zoetis Inc. (0001555280) (Subject)

    3/27/26 2:25:28 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on May 7, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur

    4/2/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Reports Fourth Quarter and Full Year 2025 Results

    Reports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 4% Organic Operational Growth in Adjusted Net Income for Fourth Quarter 2025 Reports Adjusted Net Income of $648 Million, or Adjusted Diluted EPS of $1.48, for Fourth Quarter 2025 Reports Revenue of $9.5 Billion, Growing 2%, and Net Income of $2.7 Billion, or $6.02 per Diluted Share, Increasing 8% and 10%, Respectively, on a Reported Basis for Full Year 2025 Delivers 6% Organic Operational Growth in Revenue and 7% Organic Operational Growth i

    2/12/26 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care